Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600420's ROA % is ranked better than 55.01% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 2.74
vs SHSE:600420: 3.70
Shanghai Shyndec Pharmaceutical Co (SHSE:600420) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Shanghai Shyndec Pharmaceutical Co ROA % Related Terms
Shanghai Shyndec Pharmaceutical Co ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Shyndec Pharmaceutical Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shyndec Pharmaceutical Co ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Shyndec Pharmaceutical Co's ROA % distribution charts can be found below:
* The bar in red indicates where Shanghai Shyndec Pharmaceutical Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Shanghai Shyndec Pharmaceutical Co (SHSE:600420) has a ROA % of 2.86% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Shanghai Shyndec Pharmaceutical Co and its competitors. This is 20% below median its historical median of 3.58. Over the past decade, Shanghai Shyndec Pharmaceutical Co's ROA % has ranged from 3.04 to 5.51. According to the industry distribution chart, Shanghai Shyndec Pharmaceutical Co ranks #453 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 45%.
Is Shanghai Shyndec Pharmaceutical Co's ROA % too high?
Shanghai Shyndec Pharmaceutical Co's current ROA % of 2.86% is 20% below median its 10-year median of 3.58. Over the past 10 years, this metric has ranged from a low of 3.04 to a high of 5.51. The Drug Manufacturers industry median ROA % is 2.74. Shanghai Shyndec Pharmaceutical Co's value of 2.86% is 4.4% above this industry median. Based on the distribution chart, Shanghai Shyndec Pharmaceutical Co ranks #453 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Shyndec Pharmaceutical Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shyndec Pharmaceutical Co's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Shyndec Pharmaceutical Co ranks #453 out of 1007 companies for ROA %. This puts Shanghai Shyndec Pharmaceutical Co in the upper half of its industry. The industry median ROA % is 2.74. Shanghai Shyndec Pharmaceutical Co's value of 2.86% is 4.4% above this benchmark. Historically, Shanghai Shyndec Pharmaceutical Co's own ROA % has ranged from 3.04 to 5.51 over the past decade. While the company's 10-year median is 3.58 vs. the industry median of 2.74, Shanghai Shyndec Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.74, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shyndec Pharmaceutical Co's current ROA % of 2.86% is 4.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Shanghai Shyndec Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shyndec Pharmaceutical Co's current ROA % is 2.86%, which is 20% below median its own 10-year median of 3.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shyndec Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shyndec Pharmaceutical Co (SHSE:600420) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥11.08, compared to a current price of ¥8.47 — trading 23.6% below its estimated fair value. The current ROA % is 2.86%, which is 20% below median its 10-year median of 3.58 and 4.4% above the Drug Manufacturers industry median of 2.74. Shanghai Shyndec Pharmaceutical Co's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Shanghai Shyndec Pharmaceutical Co (SHSE:600420), the current ROA % is 2.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shyndec Pharmaceutical Co (SHSE:600420) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shyndec Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.47 is trading 23.6% below its estimated GF Value™ of ¥11.08.
GuruFocus considers Shanghai Shyndec Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600420:
ROA %: 2.86% (20% below median its 10-year median of 3.58)
GF Value™: ¥11.08 vs. price of ¥8.47 (23.6% below fair value)
Industry Position: 4.4% above the Drug Manufacturers median (#453 of 1007)
No single metric tells the full story. See the SHSE:600420 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shyndec Pharmaceutical Co Business Description
Shanghai Shyndec Pharmaceutical Co Ltd engages in the research, development, production, and sale of pharmaceutical preparations, biological pharmaceuticals, chemical raw materials, and Chinese medicine formulations in China and internationally. It provides biological and chemical raw material medicines, microbial fermentation products and tablets, capsules, granules, injections, suspensions, and suppositories, as well as ointments, including product formulations.
60GF Score
Get the complete analysis for SHSE:600420
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600420 has been successfully added to your 
